Opus Genetics Statistics

Total Valuation

Opus Genetics has a market cap or net worth of $48.21 million. The enterprise value is $7.78 million.

Market Cap	48.21M
Enterprise Value	7.78M

Important Dates

The last earnings date was Thursday, May 15, 2025, before market open.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Opus Genetics has 45.48 million shares outstanding. The number of shares has increased by 29.23% in one year.

Current Share Class	45.48M
Shares Outstanding	45.48M
Shares Change (YoY)	+29.23%
Shares Change (QoQ)	+11.61%
Owned by Insiders (%)	5.36%
Owned by Institutions (%)	36.47%
Float	35.56M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.32
Forward PS	3.81
PB Ratio	9.77
P/TBV Ratio	9.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.57
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.98

Current Ratio	1.98
Quick Ratio	1.92
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-26.45

Financial Efficiency

Return on equity (ROE) is -167.55% and return on invested capital (ROIC) is -64.84%.

Return on Equity (ROE)	-167.55%
Return on Assets (ROA)	-45.36%
Return on Invested Capital (ROIC)	-64.84%
Return on Capital Employed (ROCE)	-151.76%
Revenue Per Employee	$758,389
Profits Per Employee	-$3.26M
Employee Count	18
Asset Turnover	0.27
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.88% in the last 52 weeks. The beta is 0.27, so Opus Genetics's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	-39.88%
50-Day Moving Average	0.92
200-Day Moving Average	1.11
Relative Strength Index (RSI)	54.23
Average Volume (20 Days)	2,203,585

Short Selling Information

The latest short interest is 233,621, so 0.51% of the outstanding shares have been sold short.

Short Interest	233,621
Short Previous Month	101,027
Short % of Shares Out	0.51%
Short % of Float	0.66%
Short Ratio (days to cover)	3.44

Income Statement

In the last 12 months, Opus Genetics had revenue of $13.65 million and -$58.62 million in losses. Loss per share was -$2.02.

Revenue	13.65M
Gross Profit	-16.40M
Operating Income	-36.30M
Pretax Income	n/a
Net Income	-58.62M
EBITDA	-36.28M
EBIT	-36.30M
Loss Per Share	-$2.02

Full Income Statement

Balance Sheet

The company has $41.79 million in cash and n/a in debt, giving a net cash position of $41.79 million or $0.92 per share.

Cash & Cash Equivalents	41.79M
Total Debt	n/a
Net Cash	41.79M
Net Cash Per Share	$0.92
Equity (Book Value)	23.92M
Book Value Per Share	0.11
Working Capital	23.68M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	-120.17%
Operating Margin	-265.88%
Pretax Margin	-429.42%
Profit Margin	n/a
EBITDA Margin	-265.80%
EBIT Margin	-265.88%
FCF Margin	n/a

Dividends & Yields

Opus Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.23%
Shareholder Yield	-29.23%
Earnings Yield	-118.24%
FCF Yield	n/a

Analyst Forecast

The average price target for Opus Genetics is $7.00, which is 560.38% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.00
Price Target Difference	560.38%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	38.27%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Opus Genetics has an Altman Z-Score of -4.93. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.93
Piotroski F-Score	n/a